Grade 2 patients on Jakafi® (ruxolitinib) had ~3x higher ORR1
REACH2: For all grades studied, ORRs at day 28 were higher with Jakafi vs control therapy1
aDefined as the proportion of patients who had a CR or PR as compared with baseline organ staging without the use of additional systemic therapy for aGVHD.1
*CR is defined as a score of 0 for aGVHD grading in all evaluable organs, indicating complete resolution of all signs and symptoms of aGVHD in all evaluable organs without administration of additional systemic therapies for any earlier progression, mixed response, or nonresponse of aGVHD.1
If I don’t see a response within a week or if acute GVHD begins to flare when I start tapering steroids, I then have to act quickly by adding a second-line drug.
Pashna Munshi, MD, GVHD Expert
Review the primary endpoint from REACH1
Clinically meaningful ORR across organs with Jakafi2,3
REACH1: Day 28 responses were achieved in the majority of patients treated with Jakafi and were seen across organs2,3
REACH1: ORR at Day 28 (Primary Endpoint)2,a
REACH1: ORR at Day 28 by Organ (Subgroup Analysis)2,3
Study design
Jakafi was approved by the FDA for SR aGVHD based on positive results from the REACH1 study3
REACH1 Study Design2,4
REACH2 Study Design1
Phase 2 studya
Phase 3 studyc
REACH2 data are not included in the Jakafi Prescribing Information.
aPatients had grade 2 to 4 aGVHD, as defined according to MAGIC criteria, that occurred after allogeneic hematopoietic stem cell transplantation.2
b22 patients were not included in the efficacy analysis because they received 2 or more prior anti-GVHD therapies (n=12) or did not receive an adequate dose of corticosteroids (n=10). All 71 patients were included in the safety analysis.2,4
cThe REACH2 study was conducted in 105 centers across 22 countries.1
dCrossover from control therapy to Jakafi therapy was permitted if patients did not have a response at day 28 or if they had a loss of response thereafter and received additional systemic therapy, and they did not have signs of chronic GVHD.1
eControl therapy was chosen by the investigator at the time of randomization (antithymocyte globulin, extracorporeal photopheresis, mesenchymal stromal cells, low-dose methotrexate, mycophenolate mofetil, everolimus, sirolimus, etanercept, or infliximab).1
Definition of SR aGVHD in the REACH studies1,4
In both studies, SR aGVHD was defined as disease progression after 3 days of high-dose systemic steroid treatment, lack of improvement after 7 days of such treatment, or failure to successfully taper steroid
- REACH1 also specified patients as steroid refractory if they began low-dose steroids for skin or skin plus upper GI GVHD and developed GVHD in a new organ
- Failure to taper was defined in REACH1 as the inability to achieve a 50% taper of steroid dose, and in REACH2 as the need to increase to ≥2 mg/kg/day methylprednisolone or inability to taper below 0.5 mg/kg/day for at least 7 days
aGVHD=acute graft-versus-host disease; BID=twice daily; GI=gastrointestinal; MAGIC=Mount Sinai Acute GVHD International Consortium; ORR=overall response rate; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory.
aGVHD=acute graft-versus-host disease; CI=confidence interval; CR=complete response; OR=odds ratio; ORR=overall response rate; PR=partial response; REACH=Ruxolitinib in patiEnts with refrACtory graft-versus-Host disease after allogeneic stem cell transplantation; SR=steroid-refractory.
References: 1. Zeiser R, von Bubnoff N, Butler J, et al; for the REACH2 Trial Group. Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease. N Engl J Med. 2020;382(19):1800-1810. Supplementary appendix available at: https://www.nejm.org/doi/10.1056/NEJMoa1917635. 2. Jakafi [package insert]. Wilmington, DE: Incyte Corporation. 3. Data on file. Incyte Corporation. Wilmington, DE. 4. Jagasia M, Perales MA, Schroeder MA, et al; for the REACH1 Study Group. Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial. Blood. 2020;135(20):1739-1749. Supplementary appendix available at: https://ashpublications.org/blood/article/135/20/1739/452638/Ruxolitinib-for-the-treatment-of-steroid.
